MannKind Corporation · NASDAQ:MNKD

MannKind — J.P. Morgan Healthcare Conference 2016

14 slides from MannKind's conference presentation, Jan 13, 2016

  1. Slide 1: MannKind 2.0: Blueprint for 2016

    Slide 1: MannKind 2.0: Blueprint for 2016

    MannKind 2.0: Blueprint for 2016 Our focus is patients, our passion is innovation® NASDAQ: MNKD TASE: MNKD ©2016 MannKind Corporation. All rights reserved. No copying or distribution of this material may be made without written consent of MannKind Corporation.

  2. Slide 2: Cautionary Statement

    Slide 2: Cautionary Statement

    Cautionary Statement This presentation includes forward‐looking statements relating to the development, commercialization and benefits of our products and investigational product candidates, including AFREZZA®, that are subject to certain risks and uncertainties that could cause actual results to di

  3. Slide 3: Highlights – Blueprint for 2016

    Slide 3: Highlights – Blueprint for 2016

    MNKD 2.0: Highlights – Blueprint for 2016 • CEO decision complete. – Uncertainty resolved • Afrezza® is here to stay. – Excellent user experiences – Working with Sanofi to wind down MNKD‐SNY partnership on positive terms – New MannKind‐driven sales and marketing strategy in development – New partner

  4. Slide 4: Management Decisions

    Slide 4: Management Decisions

    MNKD 2.0: Management Decisions • Al Mann remains Chairman of the Board. • Matt Pfeffer replaces Al Mann as CEO and retains title of CFO. • Principal Accounting Officer named to manage all SEC reporting obligations and general accounting requirements, reporting to CEO. • Matt Pfeffer joins MannKind B

  5. Slide 5: Afrezza – Keys to Success

    Slide 5: Afrezza – Keys to Success

    MNKD 2.0: Afrezza® – Keys to Success Increase Afrezza® market demand, driving Implement grass‐roots higher production volume and market marketing campaign utilizing penetration. social media, online media and Price Afrezza® at a more competitive level real world user experiences. compared with exist

  6. Slide 6: Afrezza Advocate Council

    Slide 6: Afrezza Advocate Council

    MNKD 2.0: Afrezza® Advocate Council • Introducing Afrezza® Advocate Council • Created and managed by MannKind, composed of a cross‐section of market experts and influencers: Afrezza® Advocate Afrezza – Experienced Afrezza® users Council – Medical professionals and diabetes care Patients/Users provid

  7. Slide 7: Diabetes Care Centers

    Slide 7: Diabetes Care Centers

    MNKD 2.0: Diabetes Care Centers “Real Time Diabetes Management, powered by Afrezza®” • Innovative new program being independently Diabetes Care Centers developed as ancillary service to existing urgent care Real Time Diabetes Management, powered by Afrezza® centers. • On‐site “plug‐in” sub‐contracto

  8. Slide 8: Technosphere Pipeline

    Slide 8: Technosphere Pipeline

    MNKD 2.0: Technosphere® Pipeline • Emphasis on fast‐trackable opportunities for licensing and partnership. – Licensing opportunities, particularly where MNKD can participate in manufacturing and/or where rapid path to market exists – Internal product programs utilizing already approved API in a nove

  9. Slide 9: Drug Candidates Currently in Development

    Slide 9: Drug Candidates Currently in Development

    MNKD 2.0: Drug Candidates Currently in Development • Treprostinil for Pulmonary Arterial Hypertension – 3 formulations tested – 2 of 3 advanced • Palonosetron for Chemo‐Induced Nausea and Vomiting – 2 formulations being tested week of January 18th • Epinephrine for Anaphylaxis – Initial formulations

  10. Slide 10: Treprostinil Technosphere Development Plan Timelines

    Slide 10: Treprostinil Technosphere Development Plan Timelines

    Treprostinil Technosphere® Development Plan Timelines 2015 2016 2017 2018 2019 4Q 1Q 2Q 3Q 4Q 1Q 2Q 3Q 4Q 1Q 2Q 3Q 4Q 1Q 2Q 3Q 4Q Technology Assessment Phase Formulation/Device Go/NoGo Decision IND Enabling Phase Pre‐IND Meeting Submit IND Go/NoGo Decision IND Phase (estimated Clinical Phase I & II

  11. Slide 11: Palonosetron Technosphere Development Plan Timelines

    Slide 11: Palonosetron Technosphere Development Plan Timelines

    Palonosetron Technosphere® Development Plan Timelines 2015 2016 2017 2018 2019 4Q 1Q 2Q 3Q 4Q 1Q 2Q 3Q 4Q 1Q 2Q 3Q 4Q 1Q 2Q 3Q 4Q Technology Assessment Phase Formulation/Device Go/NoGo Decision IND Enabling Phase Pre‐IND Meeting Submit IND Go/NoGo Decision IND Phase (estimated Clinical Phase I & II

  12. Slide 12: Epinephrine Technosphere Development Plan Timelines

    Slide 12: Epinephrine Technosphere Development Plan Timelines

    Epinephrine Technosphere® Development Plan Timelines 2015 2016 2017 2018 2019 4Q 1Q 2Q 3Q 4Q 1Q 2Q 3Q 4Q 1Q 2Q 3Q 4Q 1Q 2Q 3Q 4Q Technology Assessment Phase Formulation/Device Go/NoGo Decision IND Enabling Phase Pre‐IND Meeting Submit IND Go/NoGo Decision Human Factors IND Phase Phase I BE Data Avai

  13. Slide 13: Financial Keys to Success

    Slide 13: Financial Keys to Success

    MNKD 2.0: Financial Keys to Success • Aggressive financial control, with vigorous attention to costs and efficiency throughout organization • Successfully negotiate favorable termination terms with SNY • Execute on Afrezza® strategy to build market momentum, leading to potential fundraising efforts

  14. Slide 14: 2016 Blueprint Summary

    Slide 14: 2016 Blueprint Summary

    MNKD 2.0: 2016 Blueprint Summary • Management team re‐energized now that we are in control of our own destiny. • Afrezza® to be marketed by MannKind, with emphasis on removing cost obstacle, leading to improved insurance coverage. • Generate immediate cash and increase volume by rapid expansion into

Source: Internet Archive copy of mannkindcorp.com

More decks from MannKind Corporation

All 9 MannKind decks